The AMA&BIA 2026 Asia Medical Aesthetics Industry Congress, jointly organized by Shanghai Waigaoqiao Biomedical Industry Development Co Ltd and Taas Labs, was recently held in Pudong, establishing a high-end exchange platform that integrates government, industry, academia, research, healthcare, and investment sectors.
During the congress, five biomedical companies, along with the Bank of Communications Shanghai Free Trade Zone Branch, signed strategic cooperation agreements with Waigaoqiao Biomedical Industry Development Co Ltd, pledging to help Waigaoqiao further improve its medical aesthetics industry ecosystem.
According to the "2025 Medical Aesthetics Industry White Paper" jointly released by global consulting firm Roland Berger and Meituan Medical Aesthetics, China's medical aesthetics market is transitioning from rapid growth to high-quality development. Since 2020, the market has achieved a compound annual growth rate of 17.4 percent, with its scale expected to approach 370 billion yuan (US$53.62 billion) by 2025, and is projected to reach nearly 700 billion yuan by 2030.
The Waigaoqiao Free Trade Zone has already gathered over 900 enterprises in the biomedical industry chain, accounting for more than 44 percent of China's imports of medical devices and instruments and over 26 percent of pharmaceutical imports. It has also become a hub for regional headquarters of multinational medical aesthetics giants.
According to Zhu Yaopeng, general manager of Waigaoqiao Biomedical Industry Development Co Ltd, the zone aims to create an industry closed loop featuring coordinated development across medical aesthetics, pharmaceuticals, cosmetics, and high-end manufacturing.
